Japan 21 February 2026 - 7 March 2026

HK Express ¥4,400 Japan Sale: Routes, Dates and the Fee Travelers Must Check

HK Express launched a short-term sale on Japan–Hong Kong routes Tuesday, offering one-way fares from ¥4,400 until May 14. The lowest fare rises to at least ¥15,600 after adding a ¥11,200 fuel surcharge and other fees. The sale covers 11 routes for travel between May 26 and Sept. 30. Seats are limited and blackout dates apply.

May 12, 2026

Finance·Japan·News·Stock Market

Last Week on Japan Exchange Group: Nikkei, Topix Post Worst Week in 11 Months

The Nikkei fell 5.5% and the Topix 5.6% last week, their sharpest weekly drops since April 2025, as Middle East tensions and an oil spike triggered heavy selling. The Nikkei lost over 4,600 points in three days before rebounding on Iran talks, but volatility persisted. Finance officials pledged vigilance, while trading turnover hit multi-year highs.

March 7, 2026

Finance·Japan·News·Stock Market

Japan Exchange Group stock price: JPX heads into holiday derivatives trade as BOJ bets shift

Japan Exchange Group shares closed up 1.05% at 1,877 yen Friday as the operator prepares to keep derivatives trading open on the Feb. 23 market holiday. About 3.69 million shares traded. Investors are watching for Bank of Japan board nominations expected Feb. 25 and reacting to core inflation hitting the BOJ’s 2% target in January.

February 21, 2026

Cochlear Shares Under $100: Potential Bargain Amidst 63% Drop in 2026
May 26, 2026, 4:48 PM EDT. Cochlear Ltd's shares have plunged 63% year-to-date, falling below $100 to a decade low amid a sharp FY26 earnings downgrade. The company cut net profit guidance from $435-460 million to $290-330 million due to weaker developed market demand, hospital capacity limits, geopolitical tensions, and operational challenges. Despite these headwinds and sector-wide healthcare sell-off, analysts see the stock as oversold, with a consensus average target price of $130.70, signaling a potential 35% upside. Cochlear remains a global leader in implantable hearing devices, supported by aging populations and rising treatment awareness, with expectations for earnings recovery in the coming years.